$EW (Edwards Lifesciences Corp.)

$EW {{ '2015-11-10T14:00:48+0000' | timeago}} • SEC

$EW's liability for income taxes in connection with uncertain tax positions as of September 30, 2015 was $212.4MM. $EW expects these liabilities to be reduced by $37.9MM from offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and timing adjustments.

$EW {{ '2017-04-25T23:07:05+0000' | timeago}} • Webcast

In terms of the enrollment for low risk trial PARTNER III, $EW said it had a slow start in 2016, but is hopeful to get fully enrolled by the end of 2017.

$EW {{ '2017-04-25T21:11:05+0000' | timeago}} • Announcement

$EW expects its 2Q17 sales, excluding the impact of Germany stocking sales, to be about $810-850MM. Adjusted EPS is expected to be about $0.82-0.92.

$EW {{ '2017-04-25T21:09:18+0000' | timeago}} • Announcement

For FY17, $EW is narrowing its sales guidance to $3.2-3.2MM, from $3.0-3.4Bil. The company also raised its guidance for adjusted EPS to $3.43-3.55, from $3.30-3.45.

$EW {{ '2017-04-25T21:04:16+0000' | timeago}} • Announcement

Medical device maker $EW 1Q17 earnings rose 61% to $230.2MM or $1.06 per share, compared to $143MM, or $0.66 per share during 1Q16. Sales rose 26.7% YoY to $883.5MM. Excluding items, $EW earned $0.94, up 32%.

$PSA {{ '2017-02-23T13:58:17+0000' | timeago}} • Announcement

$PSA has appointed Leslie Heisz as an independent trustee of its Board of Trustees, effective February 23, 2017. Heisz's appointment expands the board to nine trustees, six of whom are independent. She currently serves on the boards of Kaiser Permanente and $EW.

$EW {{ '2017-02-02T00:00:03+0000' | timeago}} • Webcast

For 2017, $EW expects Transcatheter Heart Valve Therapy sales of $1.7-2Bil. For Surgical Heart Valve Therapy, the company expects sales of $750-790MM and for Critical Care, sales are expected to be $560-600MM.

$EW {{ '2017-02-01T23:48:47+0000' | timeago}} • Webcast

In 4Q16, $EW’s Critical Care sales were $146.3MM, representing an increase of 4.1% versus last year, or 2.5% on an underlying basis. Growth was driven by its Enhanced Surgical Recovery Program in the US and developing markets. In 2017, $EW expects underlying sales growth for Critical Care to be 5-7%.

$EW {{ '2017-02-01T23:45:27+0000' | timeago}} • Webcast

$EW's Surgical Heart Valve Therapy sales for 4Q16 were $189MM, down 4% compared to last year, driven by lower aortic valve sales in the US and Europe. Surgical heart valve sales were lower, primarily due to the impact of SAPIEN 3 and continued constrained mitral supply.

$EW {{ '2017-02-01T23:37:13+0000' | timeago}} • Webcast

During 4Q16, $EW’s Transcatheter Heart Valve sales in the US were $267MM and grew 41% on an underlying basis versus the prior year. Outside the US, underlying THV sales grew 19%. The company estimates total TAVR procedure growth in Europe was approx. 15% in 4Q16 compared to last year.

$EW {{ '2017-02-01T22:17:31+0000' | timeago}} • Announcement

$EW still expects 2017 sales of $3.0-3.4Bil and adjusted EPS of $3.30-3.45. For 1Q17, $EW expects sales of $760-800MM and adjusted EPS of $0.79-0.89.

$EW {{ '2017-02-01T22:15:49+0000' | timeago}} • Announcement

$EW's Transcatheter Heart Valve Therapy (THVT) sales for 4Q16 was $432MM, a 29.2% growth rate over 4Q15, or 31.8% on an underlying basis. Growth was led by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan.

$EW {{ '2017-02-01T22:15:32+0000' | timeago}} • Announcement

$EW reported a rise in 4Q16 earnings driven by higher sales and strong adoption of transcatheter aortic valve replacement (TAVR) therapy. Net income rose to $158.5MM or $0.73 per share from $140.7MM or $0.64 per share last year. Net sales grew to $767.7MM from $671.1MM. Adjusted EPS increased to $0.75 from $0.64.

$EW {{ '2016-10-25T22:39:42+0000' | timeago}} • Webcast

During 3Q16, $EW generated free cash flow of $158MM. This is defined as cash flow from operating activities of $206MM, less capital investments of $48MM. At the end of 3Q16, the company had cash, cash equivalents and short-term investments of approx. $1.2Bil. Total debt was approx. $600MM.

$EW {{ '2016-10-25T22:35:34+0000' | timeago}} • Webcast

$EW continues to expect SG&A, excluding special items, to be between 30-32% of sales for the full year 2016. The company has increased investments in structural heart initiatives with the benefit of this year's medical device excise tax suspension. R&D investments in 3Q16 grew 12% over the prior year to $113MM or 15.3% of sales.

$EW {{ '2016-10-25T22:20:20+0000' | timeago}} • Webcast

In Europe, $EW saw strong procedure growth across the majority of countries. The company estimates total procedures grew around 20% in 3Q16 compared to last year, however its growth rate was lower mainly due to reduced selling in France.

$EW {{ '2016-10-25T22:19:04+0000' | timeago}} • Webcast

Outside of the US, $EW said underlying THV sales grew 15%. The company continues to be encouraged by the strong adoption of Transcatheter Aortic Valve Replacement in Japan with the rollout of Sapien 3 expected to be completed during 4Q16.

$EW {{ '2016-10-25T22:10:57+0000' | timeago}} • Announcement

$EW raised its FY16 adjusted EPS guidance to $2.82-2.92 from prior estimate of $2.78-2.88. $EW still expects 2016 sales to be at high end of its prior $2.7-3Bil range, based on strong year-to-date results, and momentum of therapy adoption globally. For 4Q16, $EW sees sales of $750-790MM and adjusted EPS of $0.67-0.77.

$EW {{ '2016-10-25T22:07:28+0000' | timeago}} • Announcement

$EW's Surgical Heart Valve Therapy product group sales for 3Q16 rose by 1.6% from last year, or flat on an underlying basis. Globally, surgical mitral valve sales grew slightly, while aortic valve sales declined modestly, compared to last year's results.

$EW {{ '2016-10-25T22:05:43+0000' | timeago}} • Announcement

$EW's Transcatheter Heart Valve Therapy, or THVT, sales for 3Q16 jumped by 38.5% from last year, or 37.3% on underlying basis. This was driven by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan. In the U.S., THVT sales climbed 55.9%, or 54.8% on underlying basis.

$EW {{ '2016-10-25T22:03:55+0000' | timeago}} • Announcement

Medical device maker $EW reported a rise in 3Q16 earnings driven by strong global adoption of its transcatheter heart valve therapy. Net income rose to $141.4MM or $0.65 per share from $118.1MM or $0.54 per share last year. Net sales grew 20.1% to $739.4MM. Adjusted EPS jumped 25.9% to $0.68.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
POOL (Pool Corp.)
Thursday, July 20 2017 - 3:00pm
PII (Polaris Industries Inc.)
Thursday, July 20 2017 - 2:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
LAKE (Lakeland Industries Inc.)
Wednesday, June 14 2017 - 8:30pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, May 11 2017 - 12:30pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm
INGN (Inogen, Inc.)
Tuesday, May 9 2017 - 8:30pm
PKOH (Park-Ohio Holdings Corp.)
Tuesday, May 9 2017 - 2:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
KAMN (Kaman Corporation)
Thursday, May 4 2017 - 12:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
Q (Quintiles Transnational Holdings Inc.)
Wednesday, May 3 2017 - 1:00pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
WCG (WellCare Health Plans, Inc.)
Wednesday, May 3 2017 - 12:00pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm

AlphaGraphics you may like